|
| 变量 |
研究次数 |
德尔vs.ins |
|
德尔/德尔vs.ins/ins |
|
del/del+del/ins vs.ins/ins |
|
del/del vs.ins/ins+del/ins |
|
del/ins vs.ins/ins |
|
| 或（95%置信区间） |
|
或（95%置信区间） |
|
或（95%置信区间） |
|
或（95%置信区间） |
|
或（95%置信区间） |
|
|
| 总体上 |
12 |
0.95 (0.80, 1.13)R |
0.54 |
1.09 (0.75, 1.57)R |
0.67 |
0.97 (0.79, 1.19)B |
0.78 |
1.02 (0.76, 1.38)R |
0.88 |
0.94 (0.80,1.100)R |
0.43 |
| 癌症类型 |
|
|
|
|
|
|
|
|
|
|
|
| 胃癌 |
3. |
0.79 (0.72, 0.86)R |
0 |
0.90 (0.35, 2.31)R |
0.82 |
0.88 (0.53, 1.44)R |
0.60 |
0.74 (0.59, 0.91)A. |
0.005 |
0.84 (0.77, 0.98)R |
0.03 |
| 大肠癌 |
3. |
0.96 (0.65, 1.40)R |
0.82 |
0.96 (0.43, 2.16)R |
0.93 |
0.94 (0.60, 1.45)R |
0.77 |
0.99 (0.52, 1.87)R |
0.98 |
0.93 (0.65, 1.34)R |
0.71 |
| 其他 |
6. |
1.06 (0.82, 1.36)R |
0.68 |
1.24 (0.72, 2.14)R |
0.93 |
1.03 (0.76, 1.40)R |
0.84 |
1.25 (0.81, 1.91)R |
0.31 |
1.07 (0.97, 1.17)R |
0.16 |
| 种族渊源 |
|
|
|
|
|
|
|
|
|
|
|
| 中国人 |
11 |
0.98 (0.82, 1.17)R |
0.79 |
1.15 (0.79, 1.68)R |
0.47 |
1.01 (0.82, 1.24)R |
0.94 |
1.06 (0.79, 1.44)R |
0.69 |
0.96 (0.82, 1.13)R |
0.63 |
| 伊朗 |
1. |
0.61 (0.42, 0.89)R |
— |
0.43 (0.17, 1.11)R |
— |
0.58 (0.37, 3.91)R |
— |
0.51 (0.20, 1.30)R |
— |
0.61 (0.38, 0.99)R |
— |
| 控制源 |
|
|
|
|
|
|
|
|
|
|
|
| PB |
10 |
0.92 (0.76, 1.11)R |
0.38 |
1.05 (0.70, 1.57)R |
0.80 |
0.95 (0.76, 1.17)R |
0.62 |
0.99 (0.71, 1.36)R |
0.93 |
0.91 (0.78, 1.08)R |
0.28 |
| 血红蛋白 |
2. |
1.10 (0.57, 2.15)R |
0.77 |
1.30 (0.34, 4.97)R |
0.71 |
1.12 (0.49, 2.53)R |
0.79 |
1.23 (0.45, 3.36)R |
0.68 |
1.09 (0.54, 2.20)R |
0.82 |
| 癌期 |
|
|
|
|
|
|
|
|
|
|
|
| 第一阶段+第二阶段 |
7. |
1.05 (0.86, 1.28)R |
0.62 |
1.16 (0.80, 1.66)R |
0.44 |
1.06 (0.81,1.37)R |
0.68 |
1.18 (0.89, 1.56)R |
0.24 |
1.01（0.75 1.36）vR |
0.94 |
| 第三阶段+第四阶段 |
7. |
0.75 (0.50, 1.11)R |
0.15 |
0.76 (0.35, 1.61)R |
0.47 |
0.70 (0.44, 1.13)R |
0.14 |
0.94 (0.54, 1.63)R |
0.82 |
0.68 (0.43,1.08)R |
0.10 |
|
|
